Company: EUDAW
Filing Date: 2025-04-29
Form Type: 20-F
Source: 0001641172-25-006627
Chunk: 13

Company: EUDA Health Holdings Ltd
Filing Date: 2025-04-29
Form: 20-F
Item: Item 3
Chunk 13
---

the stem cell therapies which became available to CK Health for direct sales in Singapore and Malaysia in late April 2025) are in their
early stages of development and subject to rapid technological and regulatory changes. EUDA’s success will depend on its ability
to demonstrate the efficacy and value of its bioenergy cabins therapies which claim to enhance detoxification and vitality, and of the
stem cell therapies (it plans to sell), which claim to target various disorders. If consumers, healthcare providers, or regulators question
the safety, effectiveness, or affordability of these offerings, or if competitors introduce superior alternatives, EUDA’s services
may not achieve the anticipated market adoption. Negative publicity regarding patient outcomes, data privacy, or regulatory compliance
in these fields could further hinder acceptance, materially impacting the Company’s business, financial condition, and results of
operations.

EUDA’s
future success will largely depend on the integration, performance, and market execution risks of stem cell therapies developed
by a third party.

Success
of EUDA’s direct sales of stem cell therapies will largely depend on the efficacy of the stem cell therapy services rendered
by Guangdong Cell Biotech in one of its treatment centers in China, and its ability to effectively operate its treatment centers, expand storage capacity, and deliver
tailored regenerative treatments. Any delays or failures to align strategic objectives, or meet quality and service standards could
significantly harm EUDA’s brand and reputation. Additionally, the premium nature of stem cell treatments and storage may limit
demand if economic conditions weaken or competitors offer more accessible alternatives. Since EUDA’s ability to sell stem cell
therapies will depend on its agreement with an authorized distributor of Guangdong Cell Biotech, the loss of such agreement, failure
to achieve targeted storage and treatment volumes, or reputational damage from operational missteps could have a material adverse
effect on EUDA’s business, market presence, and financial condition.

EUDA’s
short operating history and the rapidly evolving nature of the industry make it difficult to assess the Company’s success and predict
the risks and challenges it may encounter.

As
EUDA’s business operations began only in 2019, its short operating history and the recent shift from medical services to the
wellness industry make it difficult to evaluate and assess the likelihood of EUDA’s success, its future business and
prospects, and the risks and challenges that EUDA may encounter. These risks and challenges include EUDA’s ability
to:

  attract                                                                            
  retain